GSK plc's fully liquid Menveo meningitis vaccine has been approved by the European Commission on November 27, 2024, for the immunization of individuals aged 2 years and older. This new form simplifies vaccination against invasive meningococcal disease (IMD), with over 82 million doses distributed globally since 2010.